Jessica Sassic, MD
Hospitalist · San Diego, CANPI 1598342529
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.3% of the total across 42 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 12.3% — the pattern of someone who eats at a lot of different presentations. Among hospitalist clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 42 payments — averaging $30.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$157
- Incyte Corporation$127
- AbbVie$114
- Merck$74
- Pharmaessentia USA Corporation$68
- E.r. Squibb & Sons, L.L.C.$63
- plus $676 from 22 others
What the payments were for
- Food & beverage$1,18092%
- Education$998%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 3 | $157 |
| Incyte Corporation | 2 | $127 |
| AbbVie | 5 | $114 |
| Merck | 3 | $74 |
| Pharmaessentia USA Corporation | 2 | $68 |
| E.r. Squibb & Sons, L.L.C. | 1 | $63 |
| AstraZeneca | 2 | $54 |
| Coherus Oncology, Inc. | 2 | $54 |
| Bayer | 2 | $48 |
| Sobi, Inc | 2 | $46 |
| Pharmacosmos Therapeutics Inc. | 1 | $38 |
| Blueprint Medicines Corporation | 1 | $31 |
| Beone Medicines USA, Inc. | 1 | $30 |
| Geron Corporation | 1 | $30 |
| Johnson & Johnson | 1 | $29 |
| Caris MPI, Inc. | 1 | $29 |
| Iovance Biotherapeutics, Inc. | 1 | $28 |
| Beigene USA, Inc. | 1 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $28 |
| Azurity Pharmaceuticals, Inc. | 1 | $28 |
| Novartis | 1 | $26 |
| AVEO Pharmaceuticals, Inc. | 1 | $26 |
| Agios Pharmaceuticals, Inc. | 1 | $25 |
| Sanofi | 1 | $24 |
| GSK | 1 | $20 |
| Rigel Pharmaceuticals, Inc. | 1 | $19 |
| Kyowa Kirin, Inc. | 1 | $18 |
| Genmab U.S., Inc. | 1 | $16 |
How this compares
$1,279 in reported general payments places this provider in the 90th percentile of 2,469 hospitalist providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atorvastatin Calcium | 16 | $122 |
| Famotidine | 14 | $58 |
| Amlodipine Besylate | 28 | $43 |
Paid to pharmacies, not to this prescriber.
Other hospitalist in San Diego
- Omar AldaasSan Diego$24K
- Danielle BrazelSan Diego$8K
- Kinaan JavedSan Diego$5K
- Gregory SeymannSan Diego$5K
- Christina BohrSan Diego$5K
- Jennifer SchneiderSanta Rosa$1.2M
- Soham ShahBakersfield$844K
- Alpesh AminOrange$428K
- Retha GoodglickSanta Monica$156K
- Robert WachterSan Francisco$75K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.